-
BofA Lowers Boston Scientific Revenue Estimates On FDA Warning, But Keeps Buy Rating
Monday, March 18, 2019 - 3:04pm | 399A Food and Drug Administration warning about possible dangers from balloons and stents coated with the drug paclitaxel is bad news for Boston Scientific Corporation (NYSE: BSX)’s Eluvia stent, but Bank of America Merrill Lynch is still recommending the stock on the basis of the company’...